S Kundu-Raychaudhuri

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
    S K Kundu
    Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305 5107, USA
    AIDS Res Hum Retroviruses 14:551-60. 1998
  2. ncbi request reprint Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization
    S K Kundu
    Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305, USA
    AIDS Res Hum Retroviruses 14:1669-78. 1998
  3. ncbi request reprint Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946)
    S Kundu-Raychaudhuri
    AIDS Clinical Trials Unit, Center for AIDS Research, Stanford University Medical Center, Stanford, California 94305 5107, USA
    AIDS Res Hum Retroviruses 17:1371-8. 2001

Collaborators

Detail Information

Publications3

  1. ncbi request reprint A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients
    S K Kundu
    Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305 5107, USA
    AIDS Res Hum Retroviruses 14:551-60. 1998
    ..However, since no effect on viral load was observed there was no evidence that this approach provided clinical benefit...
  2. ncbi request reprint Role of preimmunization virus sequences in cellular immunity in HIV-infected patients during HIV type 1 MN recombinant gp160 immunization
    S K Kundu
    Center for AIDS Research at Stanford, Stanford University Medical Center, California 94305, USA
    AIDS Res Hum Retroviruses 14:1669-78. 1998
    ..quot; This vaccine was also immunogenic as measured by gp160-specific lymphocyte-proliferative responses. However, increased immune responses did not impact the HIV load or CTL epitope sequences during therapy...
  3. ncbi request reprint Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946)
    S Kundu-Raychaudhuri
    AIDS Clinical Trials Unit, Center for AIDS Research, Stanford University Medical Center, Stanford, California 94305 5107, USA
    AIDS Res Hum Retroviruses 17:1371-8. 2001
    ....